Idenix to Host Conference Call Discussing Second Quarter 2010 Financial Results

CAMBRIDGE, Mass., July 19 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc., (Nasdaq: IDIX) announced today that it will report its financial results for the second quarter of 2010 on Monday, July 26, 2010 after U.S. financial markets close.

Idenix management will host a conference call at 4:30 p.m. ET on Monday, July 26, 2010 to discuss the company's financial results for the second quarter of 2010 and provide an update on the company's development programs.

To access the call please dial 800-471-3635 U.S./Canada or 706-758-9475 International and enter passcode 87241600 or to listen to a live webcast go to "Calendar of Events" in the Idenix Investor Center at www.idenix.com. A replay of the call will also be available from July 26, 2010, 6:30 p.m. ET until August 9, 2010, 11:59 p.m. ET.  To access the replay, please dial 800-642-1687 U.S./Canada or 706-645-9291 International and enter passcode 87241600. An archived webcast will also be available for two weeks after the call on the Idenix website.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of patients with chronic hepatitis C infection. For further information about Idenix, please refer to http://www.idenix.com.

Idenix Pharmaceuticals, Inc. Contact:

Teri Dahlman (617) 995-9905 (media)

Jonae Barnes (617) 224-4485 (investors)



SOURCE Idenix Pharmaceuticals, Inc.

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has handed Scholar Rock a rare pediatric disease designation voucher, which can allow the biotech a speedy review of its SMA med.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.